Gray platelet syndrome, abbreviated GPS, also known as alpha storage pool disease, is a rare inherited bleeding disorder. GPS is named for the gray color of enlarged platelets under light microscopy after Riesling staining. The disease is characterized by a reduction or absence of platelet alpha granules and the proteins they contain. Clinically, it is characterized by mild to moderate bleeding, often accompanied by thrombocytopenia, splenomegaly, and myelofibrosis. The incidence of GPS is very low, and thus few studies have been conducted. Early studies in the literature focused on clinical analysis, ultrastructural and biochemical changes. There is no specific treatment for GPS, and the main treatment is symptomatic hemostasis. Desmopressin, antifibrinolytic drugs, glucocorticoids, and splenectomy may be effective. Specific medications should be prescribed by a physician.